Venetoclax: A Game Changer in the Treatment of Younger AML Patients?
Cancers · 22.12.2023 · 16 (1) · 73
DOI: 10.3390/cancers16010073 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 22.12.2023. Verfasst von Matteo Molica und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology-Oncology, Azienda Universitaria Ospedaliera Renato Dulbecco, 88100 Catanzaro, Italy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The combination approach based on venetoclax (VEN) with azacytidine (AZA) has significantly improved outcomes for elderly patients with acute myeloid leukemia (AML). This innovative approach has led to higher rates of overall response, measurable residual disease (MRD)-negative remissions, and overall survival compared with AZA monotherapy. As a result, this combination has emerged as the gold-standard treatment for elderly or unfit patients with AML who are not eligible for intensive therapy. In younger, fit patients with AML, intensive induction and consolidation chemotherapy is commonly used as a first-line approach; however, relapse continues to be the main reason for treatment failure in approximately 30–40% of patients. Efforts to improve MRD-negative response rates and to facilitate the transition to allogeneic hematopoietic stem cell transplantation, particularly in high-risk AML, have inspired trials exploring the combination of intensive chemotherapy with targeted agents. VEN, a first-in-class anti-BCL2 agent, combined with intensive chemotherapy regimens has shown deep MRD-negative remissions, producing prolonged event-free survival and enhancing the transition to allogeneic transplant in first-complete-remission patients. These benefits support the incremental advantages of adding VEN to intensive chemotherapy approaches across ELN risk subcategories, and provides a robust benchmark to design future trials. In this review, we will discuss current studies assessing the efficacy of frontline regimens integrating VEN into intensive chemotherapy in younger patients with AML and specific molecularly defined subgroups.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology-Oncology, Azienda Universitaria Ospedaliera Renato Dulbecco, 88100 Catanzaro, Italy.
- Department of Hematology, Polo Universitario Pontino, S.M. Goretti Hospital, 04100 Latina, Italy.
- Hematology and Transplant Unit, Vito Fazzi Hospital, 73100 Lecce, Italy.
- Hematology Unit, Department of Hemato-Oncology and Radiotherapy Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", 89124 Reggio Calabria, Italy.
- Queens Centre for Oncology and Haematology, Castle Hill Hospital, Hull University NHS Trust, Hull HU16 5JQ, UK.
- Department of Experimental and Clinical Medicine, Magna Graecia University, 88100 Catanzaro, Italy.
ORCID-Profile: Matteo Molica, Salvatore Perrone, Stefano Molica
Zitieren
APA
Molica, M., Perrone, S., Federico, V., Alati, C., Molica, S., & Rossi, M. (2023). Venetoclax: A Game Changer in the Treatment of Younger AML Patients?. Cancers, 16(1), 73. https://doi.org/10.3390/cancers16010073
Vancouver
Molica M, Perrone S, Federico V, Alati C, Molica S, Rossi M. Venetoclax: A Game Changer in the Treatment of Younger AML Patients?. Cancers. 2023;16(1):73. doi:10.3390/cancers16010073
BibTeX
@article{Molica2023,
author = {Molica, Matteo and Perrone, Salvatore and Federico, Vincenzo and Alati, Caterina and Molica, Stefano and Rossi, Marco},
title = {Venetoclax: A Game Changer in the Treatment of Younger AML Patients?},
journal = {Cancers},
year = {2023},
volume = {16},
number = {1},
pages = {73},
doi = {10.3390/cancers16010073}
}
EUVIMED